TTrialPathMatch Me to Trials
← Back to trials
RecruitingMild Cognitive ImpairmentAlzheimer's Disease

Safety and Target Engagement of Centella Asiatica in Cognitive Impairment

Eligible age

60–85 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.

Sponsor: Oregon Health and Science University

You may qualify if…

  • ✓ Age 60-85, male and female
  • ✓ Sufficient English language skills to complete all tests
  • ✓ Sufficient vision and hearing to complete all tests
  • ✓ No known allergies to Centella asiatica
  • ✓ Absence of significant depression symptoms (Geriatric Depression Scale-15 score of \< 5).
  • ✓ Total score of \<2 on the suicidal ideation subscale (measures 3, 7, 11, 12 and 14) of the Geriatric Depression Scale.
  • ✓ Body Mass Index (BMI) greater than 17 and less than 35 at screening
  • ✓ General health status that will not interfere with the ability to complete the study

You may not qualify if…

  • ✕ Current smoking, alcohol, or substance abuse according to DSM-V criteria
  • ✕ Women who are pregnant, planning to become pregnant, or breastfeeding
  • ✕ Men who are actively trying to conceive a child or planning to within three months of study completion
  • ✕ Severe aversion to venipuncture
  • ✕ Abnormal labs indicating asymptomatic and untreated urinary tract infection
  • ✕ Cancer within the last five years, with the exception of localized prostate cancer (Gleason Grade \< 3) and non-metastatic skin cancers
  • ✕ Comorbid conditions such as type I diabetes mellitus, poorly controlled type II diabetes mellitus (HbA1c \> 7%), kidney failure, liver failure, hepatitis, blood disorders, clinical symptomatic orthostatic hypotension, and unstable or significantly symptomatic cardiovascular disease
  • ✕ Significant disease of the Central Nervous System (CNS) such as brain tumor, seizure disorder, subdural hematoma, cranial arteritis, or clinically significant stroke

Where it's recruiting

Oregon

Portland

Source: ClinicalTrials.gov · NCT05591027 · last updated 2025-04-11

Safety and Target Engagement of Centella Asiatica in Cognitive Impairm · TrialPath